Background: S-1, an oral fluoropyrimidine carbamate, is an active and well-tolerated agent against solid cancer. However, the clinical efficacy of S-1 in patients with metastatic breast cancer has not been determined. Methods: We retrospectively evaluated the efficacy of S-1 and identified its adverse effects in patients with metastatic breast cancer who had failed to respond to prior chemotherapy regimens. All the patients were treated at the National Cancer Center Hospital and received S-1 twice daily at a dose of 80 mg/m 2 for 4 weeks, followed by a 2-week rest interval. Results: Between 2003 and 2007, 37 women with metastatic breast cancer received S-1 as a third line or greater chemotherapy regimen. All the patients had been previously treated with both anthracyclines and taxanes prior to S-1 chemotherapy. The median order of S-1 administration was as a fifth-line treatment, and 23 patients (62%) received S-1 as their final anticancer drug. One (3%) partial response and two (5%) stable diseases were observed. The median time to progression (TTP) was 84 days. Grade 2 adverse events, such as diarrhea, stomatitis and neutropenia occurred in 5 (16%), 1 (3%) and 1 (3%) patients, respectively. Conclusions: S-1 was safety administered to heavily treated metastatic breast cancer patients with limited efficacy. Further evaluation of S-1 is necessary to elucidate its clinical role in breast cancer treatment.
INTRODUCTION
Treatment of patients with metastatic breast cancer (MBC) aims to prolong survival while relieving symptoms and maintaining a good quality of life (QOL).
Capecitabine is an orally administered fluoropyrimidine that has been reported to be effective in both monotherapy and combination therapy regimens. Capecitabine as a single agent produced an overall response rate (RR) of 29% and a median time to disease progression of 4.6 months in large phase II trials in taxane-pretreated MBC patients (1 -3) . Since capecitabine can sustain the QOL of MBC patients, it has been widely used as a third-line or subsequent chemotherapy regimen for heavily treated patients.
On the other hand, S-1 is another orally administered fluorinated pyrimidine that has been reported to be a welltolerated and active agent against solid cancers. In a phase II study of S-1, the RR was 41.7% and the median survival time was 872 days among taxane-pretreated patients with MBC; S-1 has been approved in Japan as a salvage chemotherapy for patients who have received anthracycline and taxane (4, 5) . In addition, S-1 has been used mainly for the treatment of cancers of the digestive tract (6 -8) , and its efficacy is well known. However, the clinical usefulness of S-1 in patients with MBC is uncertain. Here, we describe the efficacy and tolerability of S-1 in a clinical setting.
PATIENTS AND METHODS

PATIENTS
A retrospective analysis was performed on patients with MBC who received S-1 monotherapy between January 2003 and December 2006 at the National Cancer Center Hospital (NCCH). The patient population was identified from a database at the NCCH. All the patients had received chemotherapy previously. They were followed up until death or, if they were still alive, to their last visit prior to March 2007.
The best response for each patient was assessed according to the WHO criteria (8) . A complete response (CR) was defined as the disappearance of all clinical and radiographic evidence during two observations performed at least 4 weeks apart. A partial response (PR) was defined as a decrease of 30% or more in the sum of the products of the biperpendicular diameters of measurable lesions. Stable disease (SD) was defined as a ,30% decrease and a ,25% increase in the sum of the products of the biperpendicular diameters of measurable lesions and no appearance of new lesions; these conditions had to be maintained for at least 12 weeks. Progressive disease was defined as a greater than 25% increase in the sum of the products of the biperpendicular diameters of measurable lesions or the appearance of new lesions. The clinical benefit rate was defined as the proportion of patients who achieved either a CR, PR or SD. The National Cancer Institute common toxicity criteria (9) were adopted to determine toxicity.
TREATMENT S-1 was administered orally twice daily (80 mg/m
2 ) for 28 days followed by 14 days of rest. Treatment was continued until disease progression, unacceptable adverse effects or withdrawal of the patient's consent. In the case of Grade 2 or worse toxicity, S-1 administration was interrupted and not resumed until the toxicity had resolved or improved to Grade 1.
The time to progression (TTP) was calculated from the day of commencement of S-1 administration until the day of documented progression. Overall survival (OS) was calculated from the start date of S-1 to the date of death from any cause. TTP and OS were analysed according to the KaplanMeier estimates.
RESULTS
Thirty-seven patients received S-1 as a greater than secondline chemotherapy for MBC between January 2003 and December 2006 at NCCH. Table 1 shows the patient's characteristics. The median age was 49 (28 -70) years. The Eastern Cooperative Oncology Group (ECOG) performance statuses of the patients were all ,2. The sites of metastatic disease were the bone and/or soft tissue in only six patients (16%) and involved visceral sites in 31 patients (84%). Table 2 shows the chemotherapy regimens that were administered prior to S-1. The median number of chemotherapy regimens used before the administration of S-1 including adjuvant and neoadjuvant treatments, was 4, and 23 patients (62%) received S-1 as their final chemotherapy regimen. All the patients had previously received both anthracyclines and taxanes, 13 patients (35%) had received vinorelbine and 11 patients (30%) had received oral 5FU-derivatives prior to the administration of S-1. All the patients who had responded to treatment had exhibited adequate progressionfree intervals from the prior taxane administration until the subsequent taxane administration. Three patients received the same taxane regimen twice, once as adjuvant chemotherapy and the second time in combination with Trastuzumab after recurrence. Prior oral 5FU-derivatives included in other regimens were CMF (five patients), UFT (five patients), 5 0 DFUR (five patients) and CPT-11 (one patient). Sixteen patients (43%) with ER-positive diseases had received hormone therapy, and 13 patients (35%) with HER2-positive diseases had received Trastuzumab as a monotherapy or in combination with taxane or vinorelbine. The median number of administration days was 70 (6 -415 days). The RR was 3%, with no cCR and 3% (1/37) PR. The overall clinical benefit rate (CR, PR and SD for more than 6 months) was 8% (3/37). The median TTP was 84 days (range, 6 -415) ( Fig. 1; note that a colour version of this figure is available as supplementary data at http://www. jjco.oxfordjournals.org). The median OS from the start of S-1 treatment was 284 days (range, 14 -1511), and six patients (16%) were still alive at the last follow-up. Nine patients (24%) received S-1 for more than 100 days. Six out of these nine patients had visceral involvement. Two out of seven patients had oestrogen receptor-positive diseases and four of them were HER2-positive.
Overall, S-1 was well tolerated. Table 3 shows the adverse events in response to S-1 chemotherapy. Toxicities of Grade 3 or more were not reported. The most common toxicities arising from S-1 administration were diarrhea (33%) and nausea (30%). Most of the adverse events were Grade 1, and none of the S-1-related adverse events were fatal. The most frequent reasons for treatment discontinuation were disease progression (30 patients, 81%) and adverse event (seven patients, 19%). The adverse events that were encountered were Grade 2 diarrhea (five cases), Grade 2 stomatitis (one case) and Grade 2 neutropenic fever (one case).
DISCUSSION
The number of patients with MBC who have been pretreated with anthracyclines and/or taxanes are increasing. However, the optimal chemotherapy for patients with MBC who have been pretreated with both anthracyclines and taxanes has not been determined. These patients require palliative therapy that offers a chance of prolonging life with minimal toxicity according to the antitumor response and the alleviation of tumor-related symptoms.
In this study, S-1 chemotherapy produced a 3% RR and an 8% rate of clinical benefit in previously treated patients with MBC who were refractory to both anthracyclines and taxanes. The median TTP was 84 days, and 24% of the patients received S-1 for more than 100 days. These results were worse than those reported in clinical trials. This discrepancy is probably because 11 patients had received other 5FU-derivatives prior to S1, the median order of S-1 administration was fifth line (most of the patients received S-1 chemotherapy as their final treatment), and most of the patients had multiple metastatic sites (84% had visceral metastases). The toxicity of S-1, however, was mild in these heavily treated patients, and S-1 is considered to be a feasible palliative chemotherapy in heavily treated MBC patients.
Several oral 5FU-derivatives have been used to treat MBC, but only S-1 and capecitabine have been tested in taxane-refractory MBC patients (10) . The treatments were administered based upon physicians' decisions, but the reason why S-1, and not capecitabine, was selected in this study population is unclear. S-1 is a fluoropyrimidine that consists of 1-(2-tetrahydrofuryl)-5-fluorouracil (FTO), a pro-drug of 5-FU, and two other compounds, 5-chloro-2, 4-dihydroxypyrimidine (CDHP; gimestat) and potassium oxonate (OXO; otastat), in molar proportions of 1:0.4:1. CDHP is an inhibitor of dihydropirimidine dehydrogenase (DPD), which degenerates 80% of 5-FU in the liver and maintains the 5-FU level above a minimal effective concentration level. On the other hand, capecitabine is converted to 5'-DFUR either by human carboxyesterase (CE) or cytidine deaminase (CD), which is mainly localized in the human liver. 5'-DFUR is converted to the active form of 5-FU by thymidine phosphorylase (dThdPase) in human tumors. Low CE and CD activity levels are thought to protect the digestive wall and bone marrow from capecitabine toxicity.
Clinically, the reported RRs of capecitabine and S-1 in taxane-pretreated MBC patients are similar, but the toxicity profile seems to be different. Relatively severe diarrhea (14%, Grade 3) and hand-foot syndrome (10%, Grade 3) were observed in a phase II study for capecitabine (2,3), whereas the incidence of Grade 3 or severe diarrhea was relatively low (0.9%) and no hand-foot syndrome was observed in a phase II study of S-1 for MBC (4) . A direct comparison of capecitabine and S-1 monotherapy is surely necessary, and since the antitumor activity of capecitabine might be relatively low in tumor cells with high DPD levels, an evaluation of the efficacy of S-1 after progression with 174 S-1 in pretreated MBC capecitabine or in tumors with high DPD expression levels is warranted. Moreover, while the efficacy of capecitabine in combination therapy with other cytotoxics (11 -16) or as first-line chemotherapy (17) has already been reported, few evidence of the efficacy of S-1 in combination therapy or first-line chemotherapy is available (18, 19) . The efficacy and safety of S-1 in combination with molecular-targeted drugs, such as antibodies and small molecule tyrosine kinase inhibitors, are also unknown. Further studies are thus required to elucidate the clinical role of S-1 in the management of breast cancer patients.
